Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics

Cobimetinib is a kinase inhibitor indicated for use in combination with vemurafenib for treatment of unresectable/metastatic melanoma with specific BRAF mutations. Cobimetinib is extensively metabolized in liver; thus, patients with hepatic impairment (HI) might have increased cobimetinib exposure....

Descripción completa

Detalles Bibliográficos
Autores principales: Cheeti, Sravanthi, Deng, Yuzhong, Chang, Ilsung, Georgescu, Isabela, Templeton, Ian, Choong, Nicholas, Cheung, Kit Wun Kathy, Girish, Sandhya, Musib, Luna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891419/
https://www.ncbi.nlm.nih.gov/pubmed/32696585
http://dx.doi.org/10.1002/cpdd.847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891419/
https://www.ncbi.nlm.nih.gov/pubmed/32696585
http://dx.doi.org/10.1002/cpdd.847

Ejemplares similares